Our purpose is to reimagine medicine to improve and extend people’s lives. We use innovative science and technology to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.
Novartis is structured to deliver innovative products, exploit global scale, and respond to new opportunities and risks. Our divisions – Innovative Medicines and Sandoz – are supported by functional organizations with global scale. Made up of two business units – Novartis Pharmaceuticals which includes Novartis Gene Therapies, and Novartis Oncology – our Innovative Medicines Division commercializes innovative patented medicines to enhance health outcomes for patients and healthcare professionals.
Mediclinic City Hospital’s award-winning Comprehensive Cancer Centre is Dubai’s most advanced facility for the diagnosis and treatment of cancer. Located in the heart of Dubai, the Comprehensive Cancer Centre provides services for all types of male, female, adult and paediatric cancers.
It is the first centre of its kind in Dubai to combine the latest and most innovative diagnostic procedures with the treatment modalities of surgery, medical oncology and radiation therapy under one roof. The centre practises a multidisciplinary approach to cancer care, deciding on a personalised course of treatment for each patient which offers the greatest chance of success, following latest international guidelines and based on medical research.
A premier private healthcare provider in the Middle East, American Hospital, part of Mohamed & Obaid Al Mulla Group, was established in 1996 with the goal of providing world-class medical service to the community. The 254-bed, acute care, general medical/surgical private hospital has state-of-the-art facilities and an experienced team of healthcare professionals specialized in more than 40 medical and surgical specialties assuring comprehensive care. All physicians at American Hospital are American Board Certified or equivalent ensuring that patients receive an international standard of care in the UAE.
American Hospital is the first hospital in the Middle East to be awarded the JCI while its laboratory is the first in the private sector in the region to be accredited by the College of American Pathologists. The hospital is also the inaugural member of the prestigious Mayo Care Network. Further, American Hospital’s cancer program was the first to offer comprehensive one-stop care in Dubai. The Life Support Training Centre at American Hospital Dubai is the first in a private hospital in the UAE to be an American Heart Association (AHA) International Training Center.
Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health. Our mission is to change the management of disease worldwide by using information gained from a simple blood draw to proactively inform treatment. Our cutting-edge technology platform combines novel molecular biology techniques with a suite of bioinformatics software, allowing detection down to a single molecule in a tube of blood.
Pure Health is an integrated healthcare solutions provider with a diversified services portfolio of hospital management, laboratory services, and medical solutions, helping people live a healthier life through a new standard of healthcare.
Pure Health manages a network of eight hospitals, and over 150 laboratories (the region’s largest network). Pure Health drives the growing healthcare ecosystem by supplying medical and diagnostic devices to a customer base of over 300 healthcare providers offering them customised solutions towards improvement of financial, operational, and clinical performance.
Pure Health has been at the forefront of fighting the COVID-19 pandemic through providing screenings and vaccine administration to UAE citizens and residents.
Emirates American for Medical Services, LLC was established in 2007 as a holding company for a joint partnership between H.H. Dr. Sheikh Sultan Bin Khalifa Bin Zayed Al Nahyan and Dr. Aly Abdel Razek, M.D. President and Chairman of Medical Resources International. They envisioned and founded this State of the Art comprehensive cancer treatment center known as the Gulf International Cancer Center now operated, managed and chaired by Proton Partners International Healthcare LLC, (PPIHC) since 2016. Gulf International Cancer Center’s Vision is to lead as the oncology healthcare provider for cancer treatment in the UAE and Gulf, setting a new standard of outstanding care and exemplary patient service. Gulf International Cancer Center is a beacon lighting the way for future healthcare endeavors in the region.
IPS Genomix stands for innovation that benefit to the community. Specialized in the latest prognostic, predictive and personalized medicine, IPS Genomix gives treating physicians access to important and clinically relevant genomic information further to testing human specimens in the US or European partnering laboratories accredited and specialized in this field.
The treating physician can then individualize the treatment of his/her patients to enhance the prevention and/or treatment of certain conditions and diseases. IPS Genomix brings this intelligent and groundbreaking new solution to treating physicians and their patients in the Middle East and Africa thanks to partnerships with multinational companies (e.g. Caris Life Sciences).
As City Pharmacy is one of the leading Pharmaceutical, Medical equipment, and consumables companies in the UAE, we are the proud sole distributors for ICU Medical IV therapy, chemotherapy products, and equipment in the country.
ICU Medical is one of the most renown IV therapy- Specialized companies in the world. With a wide range of IV sets, needle free connectors and extensions, Closed-System transfer devices, and IV infusion pumps, we are focused on bringing you intuitive, patient-centric IV products and services that provide meaningful clinical differentiation, consistent innovation, and superior value. Starting from the pharmacy into the patient side we design our products to work within your existing workflows to minimize disruption and maximize the time you spend with patients. For more than three decades, we have been dedicated to a singular purpose—improving the safety and efficiency of IV therapy.
Immedica has developed a well-tailored and efficient approach for the successful management of rare disease products, including orphan drugs. In optimizing access to the products, we offer a package of complete commercial pharmaceutical services and strategies including marketing and sales via an experienced rare disease field force, navigation of the complex pricing and reimbursement environment, tender management, regulatory and medical affairs, drug safety and quality assurance. Immedica also runs an effective logistics chain for distribution of products, all over Europe and the Middle East. We have long-established relations and networks with key opinion leaders and other stakeholders across the rare disease areas.
Immedica always puts the patients first, and in a partnership, assets get full commitment and support in order for us to bring the valuable medicines to patients. Our principal philosophy is that everything we do should add value for our customers, partners and most importantly the patients. Immedica’s senior leadership has a long and proven track record of operating in mutually fruitful commercial partnerships, and our company possesses extensive experience from, and flexibility on, different partnership structures. Immedica is continuously searching for new products which could support in fulfilling unmet medical needs in Europe and the Middle East.